Adjusted HRs (95% CIs) of selected outcomes comparing DOAC use in nonvalvular AF patients with active cancer, MarketScan, 2010-2014
| . | No. of events . | Person-years . | No. of events . | Person-years . | HR (95% CI) . | P . |
|---|---|---|---|---|---|---|
| Dabigatran user (n = 859) | Matched rivaroxaban user (n = 922) | |||||
| Ischemic stroke | 9 | 980 | 3 | 1059 | 7.61 (1.52, 38.12) | .01 |
| Severe bleeding | 22 | 968 | 22 | 1045 | 1.07 (0.50, 2.32) | .86 |
| Other bleeding | 12 | 972 | 19 | 1030 | 0.81 (0.32, 2.06) | .65 |
| VTE* | 13 | 956 | 33 | 982 | 0.47 (0.21, 1.04) | .06 |
| Asthma (control outcome) | 11 | 978 | 15 | 1049 | 1.66 (0.58, 4.77) | .34 |
| Apixaban user (n = 1126) | Matched rivaroxaban user (n = 2016) | |||||
| Ischemic stroke | 3 | 568 | 13 | 1123 | 0.52 (0.13, 2.17) | .37 |
| Severe bleeding | 10 | 567 | 43 | 1112 | 0.29 (0.13, 0.65) | .002 |
| Other bleeding | 9 | 554 | 31 | 1088 | 0.64 (0.28, 1.49) | .3 |
| VTE* | 10 | 556 | 92 | 976 | 0.23 (0.12, 0.47) | <.0001 |
| Asthma (control outcome) | 14 | 565 | 25 | 1116 | 0.75 (0.34, 1.67) | .48 |
| . | No. of events . | Person-years . | No. of events . | Person-years . | HR (95% CI) . | P . |
|---|---|---|---|---|---|---|
| Dabigatran user (n = 859) | Matched rivaroxaban user (n = 922) | |||||
| Ischemic stroke | 9 | 980 | 3 | 1059 | 7.61 (1.52, 38.12) | .01 |
| Severe bleeding | 22 | 968 | 22 | 1045 | 1.07 (0.50, 2.32) | .86 |
| Other bleeding | 12 | 972 | 19 | 1030 | 0.81 (0.32, 2.06) | .65 |
| VTE* | 13 | 956 | 33 | 982 | 0.47 (0.21, 1.04) | .06 |
| Asthma (control outcome) | 11 | 978 | 15 | 1049 | 1.66 (0.58, 4.77) | .34 |
| Apixaban user (n = 1126) | Matched rivaroxaban user (n = 2016) | |||||
| Ischemic stroke | 3 | 568 | 13 | 1123 | 0.52 (0.13, 2.17) | .37 |
| Severe bleeding | 10 | 567 | 43 | 1112 | 0.29 (0.13, 0.65) | .002 |
| Other bleeding | 9 | 554 | 31 | 1088 | 0.64 (0.28, 1.49) | .3 |
| VTE* | 10 | 556 | 92 | 976 | 0.23 (0.12, 0.47) | <.0001 |
| Asthma (control outcome) | 14 | 565 | 25 | 1116 | 0.75 (0.34, 1.67) | .48 |
Adjusted for age, sex, CHA2DS2-VASc score, prior history of the outcome, and HDPS.
Patients with prevalent VTE excluded from the analysis.